Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Kentaro Kogushi, Toshio Ogawa & Shunya Ikeda. (2020) An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan. Expert Review of Pharmacoeconomics & Outcomes Research 20:5, pages 455-471.
Read now
Read now
Lieven Annemans. (2019) A proposal for value informed, affordable (“via”) prices for innovative medicines. Journal of Medical Economics 22:11, pages 1235-1239.
Read now
Read now
Nigel SB Rawson & John Adams. (2017) Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?. ClinicoEconomics and Outcomes Research 9, pages 721-730.
Read now
Read now
Articles from other publishers (15)
Charalampos Tzanetakos & George Gourzoulidis. (2023) Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece. Value in Health Regional Issues 36, pages 18-26.
Crossref
Crossref
Carolina Iglesias-López, Antònia Agustí, Antoni Vallano & Mercè Obach. (2023) Financing and Reimbursement of Approved Advanced Therapies in Several European Countries. Value in Health 26:6, pages 841-853.
Crossref
Crossref
Jiro Akimoto & Tomoyuki Takura. (2022) The Cost-Effectiveness Evaluation of the Intraoperative Additional Photodynamic Therapy for the Treatment of Newly Diagnosed Glioblastoma光線力学的療法（Photodynamic therapy: PDT）の費用対効果～悪性脳腫瘍に関して～. The Journal of Japan Society for Laser Surgery and Medicine 43:2, pages 65-73.
Crossref
Crossref
Victoria Charlton. (2022) The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies. Health Economics, Policy and Law, pages 1-27.
Crossref
Crossref
Cormac Kennedy, Laura McCullagh, Roisin Adams, Lea Trela-Larsen, Lesley Tilson & Michael Barry. (2021) Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. Value in Health 24:10, pages 1402-1406.
Crossref
Crossref
Giuseppe Boriani, Marco Vitolo, David Justin Wright, Mauro Biffi, Benedict Brown, Khaldoun G Tarakji & Bruce L Wilkoff. (2021) Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRX™ antibacterial envelope. EP Europace 23:Supplement_4, pages iv33-iv44.
Crossref
Crossref
Nigel S. B. Rawson. (2020) Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?. Journal of Population Therapeutics & Clinical Pharmacology 27:1, pages e48-e64.
Crossref
Crossref
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C. Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P. Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso GuerraJr.Jr., Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O. Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C. Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell & Alan Haycox. (2018) Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health 6.
Crossref
Crossref
Necdet B. Gunsoy, Scott Doyle, Sarah M. Cockle, Robyn von Maltzahn & Yumi Asukai. (2018) WITHDRAWN: Evaluating the Impact of Using a Generic versus a Disease-Specific Quality-of-Life Instrument in Cost-Utility Analyses: A Case Study in Severe Asthma. Value in Health.
Crossref
Crossref
Praveen Thokala, Jessica Ochalek, Ashley A. Leech & Thaison Tong. (2018) Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 36:5, pages 509-522.
Crossref
Crossref
Scott Grosse, Cora Peterson, Rahi Abouk, Jill Glidewell & Matthew Oster. (2017) Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review. International Journal of Neonatal Screening 3:4, pages 34.
Crossref
Crossref
Thomas D. Szucs, Martina Weiss & Guido Klaus. (2016) The enigma of value: in search of affordable and accessible health care. The European Journal of Health Economics 18:6, pages 667-670.
Crossref
Crossref
Klemens Wallner, A. M. James Shapiro, Peter A. Senior & Christopher McCabe. (2016) Cost effectiveness and value of information analyses of islet cell transplantation in the management of ‘unstable’ type 1 diabetes mellitus. BMC Endocrine Disorders 16:1.
Crossref
Crossref
MeiLan K Han, Carlos H Martinez, David H Au, Jean Bourbeau, Cynthia M Boyd, Richard Branson, Gerard J Criner, Ravi Kalhan, Thomas J Kallstrom, Angela King, Jerry A Krishnan, Suzanne C Lareau, Todd A Lee, Kathleen Lindell, David M Mannino, Fernando J Martinez, Catherine Meldrum, Valerie G Press, Byron Thomashow, Laura Tycon, Jamie Lamson Sullivan, John Walsh, Kevin C Wilson, Jean Wright, Barbara Yawn, Patrick M Zueger, Surya P Bhatt & Mark T Dransfield. (2016) Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. The Lancet Respiratory Medicine 4:6, pages 473-526.
Crossref
Crossref
. (2015) Agencies consider multiple factors when ICERs above thresholds. PharmacoEconomics & Outcomes News 737:1, pages 8-8.
Crossref
Crossref